Business Wire

Weber Inc. Launches 1952 Ventures LLC and Announces Senior Leadership Appointments and Promotions

Share

Weber Inc. (“Weber” or “the Company”) today announced it has established 1952 Ventures LLC, a new subsidiary that will serve as an accelerator of new growth platforms and brand extensions for Weber in the areas of product, technologies, and partnerships. Troy Shay, Chief Commercial Officer of Weber Inc., has been appointed Chief Executive Officer of 1952 Ventures LLC and Chief Growth Officer of Weber. The Company also announced five additional senior leadership appointments and promotions in its Global Operations and Americas and European Operating Segments.

Troy Shay, Chief Executive Officer, 1952 Ventures LLC and Chief Growth Officer of Weber Inc.

Since joining Weber in 2018, Mr. Shay has led the Company’s Americas business in the U.S., Canada, and Latin America. He has been instrumental in managing several strategic Weber commercial initiatives, resulting in exceptional company growth. In his new position, effective December 1, 2021, Mr. Shay will focus on future business development initiatives for Weber and is responsible for identifying and developing new platforms that expand the Company’s product and brand portfolios globally.

Beau Warren Promoted to President Weber Americas

Effective December 1, 2021, Beau Warren will serve as President Weber Americas, succeeding Mr. Shay. Mr. Warren, who joined Weber in 2019 from Fortune Brands, currently serves as Senior Vice President and General Manager of Weber’s U.S. business, which has shown substantial revenue expansion under his leadership.

Michael Jacobs Appointed Chief Operating Officer of Weber Inc.

Michael Jacobs, Chief Supply Chain Officer, has been appointed to the role of Chief Operating Officer. Mr. Jacobs joined Weber in 2014 and most recently served as Chief Supply Chain Officer, leading the Company’s multi-continent manufacturing footprint and global supply chain. In his new position, Mr. Jacobs will oversee end-to-end operations for Weber, from its innovation engine to manufacturing and its customer-facing supply chain.

Jennifer Bonuso Promoted to Senior Vice President and General Manager, Global Product of Weber Inc.

Jennifer Bonuso will serve as Senior Vice President and General Manager, Global Product. Since joining Weber in 2019 from Honeywell and Whirlpool, Mrs. Bonuso has led the creation and management of an industry-leading new product pipeline.

Hans-Jurgen Herr Appointed President Emeritus and EVP Growth Projects, Weber EMEA

Effective December 1, 2021, Hans-Jürgen Herr, currently President of Weber EMEA, will transition to President Emeritus and EVP Growth Projects as part of a planned multi-year succession process. An 18-year veteran of Weber, Mr. Herr has served as President of Weber EMEA for nine years. Through his tenure as President, he has nearly tripled Weber’s business across the region. In his new role, Mr. Herr will lead several growth projects for the Company and serve in an advisory capacity for Weber’s large and growing EMEA business.

Steffen Hahn, Ph.D., Appointed In-Coming President of Weber EMEA

Dr. Steffen Hahn, currently Senior Vice President Commercial of Weber EMEA, will succeed Mr. Herr as President of Weber EMEA, effective December 1, 2021. Dr. Hahn joined Weber in early 2020 as part of a planned succession strategy. Since joining the Company, he has significantly contributed to accelerating Weber’s growth in EMEA. Before Weber, Dr. Hahn worked across a range of successful consumer business engagements at McKinsey & Company and Procter & Gamble.

“The start of 1952 Ventures along with the appointments and promotions of several senior leaders position us for continued growth and market leadership,” said Chris Scherzinger, Chief Executive Officer of Weber. “I believe a company’s success reflects the talents of its team, and we have the best global team in the business. We’ll leverage the market-leading strength of our people, our iconic brand, and our worldwide reach to drive new growth platforms and innovative ventures with world-class execution.”

“I want to thank Troy, Beau, Mike, Jennifer, Hans, and Steffen for their leadership and commitment to our Weber team members around the world and our loyal consumers and fans. I am delighted each of them will continue to work closely with me to execute our strategic plan and take our cherished brand to new heights,” added Mr. Scherzinger.

ABOUT WEBER INC.

Weber Inc., headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original charcoal grill nearly 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet and electric grills, smokers, and accessories designed to help outdoor cooking enthusiasts discover what’s possible. Earlier this year, the Company acquired June Life Inc., a smart appliance and technology company, to accelerate the development of its Weber Connect® technology and digital products. Weber offers its barbecue grills and accessories, services, and experiences to a passionate community of millions across 78 countries.

Weber Connect® is a registered trademark of Weber-Stephen Products LLC.

FORWARD-LOOKING STATEMENTS

This press release contains various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which represent Weber’s expectations or beliefs concerning future events. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed in the section titled “Risk Factors” in our Registration Statement (Registration No. 333-257824) on Form S-1. Our future results could be affected by a variety of other factors, including uncertainty of the magnitude, duration, geographic reach, impact on the global economy and current and potential travel restrictions of the COVID-19 outbreak, the current, and uncertain future, impact of the COVID-19 outbreak on our business, growth, reputation, prospects, financial condition, operating results (including components of our financial results), and cash flows and liquidity, risks relating to any unforeseen changes to or effects on liabilities, future capital expenditures, revenues, expenses, earnings, synergies, indebtedness, financial condition, losses and future prospects, the ability to realize the anticipated benefits and synergies from business acquisitions in the amounts and at the times expected, the impact of competitive conditions, the effectiveness of pricing, advertising, and promotional programs; the success of innovation, renovation and new product introductions; the recoverability of the carrying value of goodwill and other intangibles, the success of productivity improvements and business transitions, commodity and energy prices, transportation costs, labor costs, disruptions or inefficiencies in supply chain, the availability of and interest rates on short-term and long-term financing, the levels of spending on systems initiatives, properties, business opportunities, integration of acquired businesses, and other general and administrative costs, changes in consumer behavior and preferences, the effect of U.S. and foreign economic conditions on items such as interest rates, statutory tax rates, currency conversion and availability, legal and regulatory factors including the impact of any product recalls; and business disruption or other losses from war, pandemic, terrorist acts or political unrest.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR RELATIONS CONTACT:
investors@weber.com
Brian Eichenlaub

MEDIA CONTACT:
media@weber.com
Kristina Peterson-Lohman

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye